A bone marrow support-cell protein (CNOT6L) that may drive progression to acute myeloid leukemia
Project 3: Role of stromal cell-activated CNOT6L deadenylase in driving AML transformation
The team is checking whether higher CNOT6L levels in bone marrow support cells help drive progression from myelodysplastic syndromes (MDS) to acute myeloid leukemia (AML) in people with blood disorders.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Columbia University Health Sciences NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11181658 on NIH RePORTER |
What this research studies
Researchers will use mouse models that activate β-catenin in bone-forming cells and blood or bone marrow samples from patients whose MDS progressed to AML to study CNOT6L levels and activity. They will force CNOT6L expression in hematopoietic stem and progenitor cells to see if it causes AML-like disease and inactivate CNOT6L to see if that reverses or blocks transformation. The team will compare CNOT6L expression in patient cohorts and animal models and study how chronic inflammation (for example, IL-1 exposure) affects CNOT6L in stem cells. These experiments aim to show whether keeping CNOT6L low supports normal myeloid differentiation and prevents leukemia evolution.
Who could benefit from this research
Good fit: Ideal candidates to participate or donate samples would be people with MDS, especially those at high risk of progression or who recently progressed to AML, and patients with AML.
Not a fit: People without bone marrow disorders or with cancers unrelated to myeloid disease are unlikely to gain direct benefit from this project.
Why it matters
Potential benefit: If confirmed, this work could identify CNOT6L as a target for therapies to prevent or reverse progression from MDS to AML.
How similar studies have performed: Preclinical mouse models and analyses of patient samples support a role for CNOT6L in transformation, but targeting CNOT6L in patients remains untested.
Where this research is happening
New York, United States
- Columbia University Health Sciences — New York, United States (Active)
Researchers
- Principal investigator: Kousteni, Stavroula — Columbia University Health Sciences
- Study coordinator: Kousteni, Stavroula
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.